The Added Value of Multidisciplinary Care for Patients with Pancreatic Cancer

The clinical/radiographic stage of disease was changed in 19% of patients after review of pre-referral imaging and when necessary, repeat imaging interpreted by an experienced radiologist. To assign a clinical/radiographic stage to a patient (and their CT images) assumes that the multidisciplinary group has agreed on the definitions of resectable, locally advanced (to include borderline resectable) and metastatic disease. As the manuscript infers, this is rarely the case. In fact, there was recently a consensus conference coordinated by Dr. Jean-Nicolas Vauthey and supported by the SSO and the AHPBA to generate working definitions of these stages of disease; this important manuscript is forthcoming. If physicians of different specialties can agree on the radiographic stages of disease, then stage specific treatment is possible, and over time, more uniform. The clinical/radiographic staging system in use at our institution is presented in Table 1. However, accurate staging is possible only if the cross-sectional imaging studies are done well and interpreted accurately. Accurate interpretation of CT or MRI images by radiologists of significantly less experience than Dr. Fishman requires a report template to insure that all necessary information is contained in the report – information needed to accurately apply the proper stage of disease. The template in use at our institution appears in Table 2. Such working definitions allow for patients to be initially evaluated by physicians of any specialty and their disease extent accurately determined.

The treatment recommendation was altered in 24% of patients based on repeat imaging and multidisciplinary review. If we agree that for most solid tumors, treatment is stage specific, then the clinician needs to know 3 basic pieces of information to develop a treatment recommendation: histologic diagnosis, stage of disease, and performance status of the patient. The multidisciplinary review/interaction (whether in an outpatient clinic or a tumor board environment) enhances cross-talk between specialties and allows for the development of consensus regarding stage-specific (and to some degree institution-specific) treatment algorithms (Table 3). Having physicians of different specialties reach consensus on treatment recommendations requires that they have meaningful academic interchange – the multidisciplinary clinic clearly serves that purpose, but other potentially less time-consuming alternatives (multidisciplinary outpatient centers which are disease-specific not specialty-specific, weekly multidisciplinary conferences, office space allocation which considers disease orientation not just departmental affiliation) may also be available.

Enrollment in clinical trials was greatly enhanced by the development of the multidisciplinary clinic. Point well taken, and for a disease with such an aggressive natural history such as pancreatic cancer, attention to the enrollment of patients in clinical trials is our obligation (not our option). However, the success of such efforts is clearly influenced by the presence or absence of an academic agenda, infrastructure support for clinical trials, and patterns of reimbursement. This may be a much more complicated problem to fix for many institutions than the other two examples cited above.